Howard C. Dittrich

Howard C.
Dittrich founded NovaCardia, Inc. in 2001, where he worked as Chief Medical Officer & SVP-Regulatory Affairs from 2001 to 2007, Farapulse, Inc. in 2014, where he worked as Chairman from 2014 to 2016, Sequel Pharmaceuticals, Inc. in 2007, where he worked as Chief Medical Officer from 2007 to 2011, Laguna Pharmaceuticals, Inc. in 2006, where he worked as Chief Medical Officer from 2011 to 2015, and Advanced Endovascular Therapeutics, Inc. in 2015, where he is working as President & Director from 2015.
Dr. Dittrich also founded Hawkeye Therapeutics, Inc., where he worked as Chief Medical Officer.
Dr. Dittrich also currently works at François M.
Abboud Cardiovascular Research Center, as Chairman from 2012 and Cirius Therapeutics, Inc., as Chief Medical Officer.
Dr. Dittrich also formerly worked at Mast Therapeutics, Inc., as Independent Director from 2014 to 2017, Savara, Inc., as Director, Alliance Pharmaceutical Corp., as Chief Medical Officer & Vice President from 2001 to 2002, Molecular Biosystems, Inc., as Vice President-Research & Regulatory Affairs from 1996 to 2002, Sorbent Therapeutics, Inc., as Chief Medical Officer from 2012 to 2014, the University of California, Berkeley, as Member, and the University of California San Diego, as Clinical Professor in 2011.
Dr. Dittrich received his undergraduate degree from the University of Iowa and doctorate degree from the University of Iowa Carver College of Medicine.